Aman Khan
CFO, Illustratum


We are ILLUSTRATUM, a British biotechnology company that has developed a biological diagnostic marker (DARC) which, combined with a state-of-the-art AI powered algorithm, can detect glaucoma years ahead of the current standard of care. DARC combines this biological marker with a specially designed fluorescent dye to label stressed, sick and apoptosing retinal ganglion cells (RGC) in patients with early glaucoma. Using commonly available ophthalmic imaging instruments, DARC can then be used to image nerve cell death. This is the first time any group has achieved this in vivo in humans. By detecting cellular stress and apoptosis, DARC can be used as an exploratory bio-marker by pharma companies engaged in developing treatments for glaucoma and macular degeneration (AMD). DARC can enable these companies to significantly de-risk clinical development programmes.

Matchmaking Information

Processing. Please wait.